Pulse Biosciences (NASDAQ:PLSE – Get Free Report) and NexGel (NASDAQ:NXGL – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, dividends, earnings, institutional ownership and profitability.
Profitability
This table compares Pulse Biosciences and NexGel’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pulse Biosciences | -6,755.78% | -94.42% | -79.96% |
| NexGel | -51.26% | -121.18% | -41.15% |
Analyst Recommendations
This is a breakdown of current recommendations for Pulse Biosciences and NexGel, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pulse Biosciences | 1 | 0 | 5 | 1 | 2.86 |
| NexGel | 1 | 2 | 0 | 0 | 1.67 |
Insider and Institutional Ownership
77.0% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 2.2% of NexGel shares are owned by institutional investors. 74.0% of Pulse Biosciences shares are owned by company insiders. Comparatively, 19.8% of NexGel shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Risk and Volatility
Pulse Biosciences has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500. Comparatively, NexGel has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500.
Earnings and Valuation
This table compares Pulse Biosciences and NexGel”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pulse Biosciences | $350,000.00 | 10,884.99 | -$72.78 million | ($1.18) | -45.60 |
| NexGel | $11.42 million | 0.17 | -$3.00 million | ($0.71) | -0.28 |
NexGel has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than NexGel, indicating that it is currently the more affordable of the two stocks.
Summary
Pulse Biosciences beats NexGel on 8 of the 15 factors compared between the two stocks.
About Pulse Biosciences
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
About NexGel
NEXGEL, Inc. manufactures high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels. Its products are used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company was formerly known as AquaMed Technologies, Inc. and changed its name to NEXGEL, Inc. in November 2019. The company was incorporated in 2009 and is based in Langhorne, Pennsylvania.
Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
